AZD4063

Phase 1Small molecule

AstraZeneca

AZD4063 is one of 9 small molecule programs targeting Dilated Cardiomyopathy. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Dilated CardiomyopathyRecruiting

Dilated CardiomyopathyPhase 1

Recruiting

Competition

Competitive Landscape

12 competitors in Dilated Cardiomyopathy

#DrugCompanyPhaseTrials

Crestor

AstraZeneca

Approved

—2

Rapamune

PPrism Pharmaceuticals

Approved

1 3

Lotensin

VValidus Pharmaceuticals

Approved

1 4

Atacand

AstraZeneca

Phase 3

1 5

Danicamtiv

Bristol-Myers Squibb

Phase 3

3 6

Avandia

Natrecor

1 8

Other

AstraZeneca

Preclinical

1 9

AZD4063

AstraZeneca

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 1Recruiting

Dilated Cardiomyopathy

NCT07241104

Clinical

Trials by Indication[1]

Dilated Cardiomyopathy1 trial

A Phase I First-in-human Study to Investigate Safety, Tolerability, and Pharmacokinetics of AZD4063 in Adults With Phospholamban R14del Dilated Cardiomyopathy

Recruiting· AstraZeneca logo

AstraZeneca·Phase 1·NCT07241104·23 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for AZD4063. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AZD4063 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for AZD4063. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AstraZeneca company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: AstraZeneca

AZD4063

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Dilated Cardiomyopathy1 trial

References

Drug Info

Quick Facts

Related News